about
Carbon monoxide and hydrogen sulfide: gaseous messengers in cerebrovascular circulation.Improved targeting of miRNA with antisense oligonucleotidesCrystal structures of DNA:DNA and DNA:RNA duplexes containing 5-(N-aminohexyl)carbamoyl-modified uracils reveal the basis for properties as antigene and antisense moleculesDetermination of therapeutic oligonucleotides using capillary gel electrophoresis.Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelSecondary structure of a conserved domain in an intron of influenza A M1 mRNASplicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.Antisense oligonucleotide therapy for neurodegenerative disease.Antisense oligonucleotides as therapeutics for hyperlipidaemias.Alicaforsen therapy in inflammatory bowel disease.Hairpin ribozyme-antisense RNA constructs can act as molecular Lassos.MicroRNAs as targets for antisense-based therapeutics.DNAzymes and cardiovascular disease.The delivery of therapeutic oligonucleotidesDisposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.Therapeutic prospect of Syk inhibitors.Epidermal-specific deletion of CD44 reveals a function in keratinocytes in response to mechanical stress.Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies.New therapeutic targets for amyotrophic lateral sclerosis.Factor XI and XII as antithrombotic targets.Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery.Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides.Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells.Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy SubjectsNuclease resistant oligonucleotides with cell penetrating properties.Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53.Gene silencing by synthetic U1 adaptors.Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2.Evidence for a dual functional role of a conserved histidine in RNA·DNA heteroduplex cleavage by human RNase H1.Molecular Mechanisms of Antisense Oligonucleotides.Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides.Assessment of the effects of ISIS 2302, an anti-sense inhibitor of human ICAM-1, on cellular and humoral immunity in mice.Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2'-MOE-ASOs.Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes.Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells.Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides.A High-Throughput Process for the Solid-Phase Purification of Synthetic DNA Sequences.
P2860
Q24537955-7DAD54B1-F201-40E8-B591-05F4AA3E89FEQ24547511-78B2C9AE-CAFB-48FE-ABB7-855C133C5CD4Q27643996-C1B4E50B-FE72-479D-85D5-60273F84C3B1Q34013085-B8BA3BDA-AD10-495C-BDA2-DD80EECDDAAAQ34030144-780161D1-E3D1-40B6-B4E0-87A5A74EBA3FQ34070147-E2A7B046-AB6D-4591-BC9A-F20B856C3F46Q34353625-9CF67A34-4DEE-4AC4-98A0-39F29F771FB9Q34830633-6670B0EE-8588-4473-A1C7-27C616B5074CQ36194069-F4B5603C-2269-4693-9929-CBF93525F7E8Q36273416-FF3DBFDB-7A58-4C43-94FE-2AF7CE0AAC92Q36986720-FFB34795-1E8F-4E48-A18C-7B7A14A3AF18Q37032639-EE3B6DCE-3A02-4532-98CD-D99E02862D42Q37153589-C03EEF66-FA1A-4395-BFD2-8D5780511628Q37210936-41C2AD9E-6BD8-4BFF-9CEC-B8A958351340Q37238891-5B58AC42-E1B8-4D92-BC07-E15AEA28D3FBQ37577893-1D11E3A2-1197-4197-800D-D69455560773Q37603281-F766DCBD-2FA2-4C38-8A6A-B0C40A5FDAC6Q37677072-76AD9C31-C138-4320-8A8D-7AB868B80B4EQ37816447-235324D5-BBBC-4989-A3C4-313F87FDA86DQ37897854-07621E1F-A40C-4961-B779-7678987BF1A1Q37974719-3B77EABD-F30A-4DEC-A7FC-E9DF937CC48DQ38291806-BF9043CD-D4D3-453C-9F15-117D52A3A8FBQ38346601-DDFBE47B-A832-4A5B-A683-1FB48F40CA46Q38629087-101232DC-51E2-454C-B8E6-C09AD5BC211BQ38911554-5492F51C-B0E3-4B19-87D0-34F0F61931E7Q39312249-65B1BA77-C592-4CB3-9184-A30D2791241FQ39883594-4CDA5EBE-5A9F-4653-AC52-93970346845CQ40244901-31091220-94B5-45D0-9034-4B83FB1908D3Q41863852-6D0EC05C-B963-407A-AE78-1FF5EDE3D5EEQ42293314-9E418875-642F-4B3F-B355-9FB59046298AQ42418345-2E5E81A5-8423-409D-A81D-E54A7F65CB1EQ46092877-EC998455-CCD5-4B60-95D7-27B44EA9C59BQ47097992-10A5E418-24F0-4123-8A9E-0D4502BE0210Q47156365-E5714C4C-9745-4928-9275-233E668F03D7Q49424319-1CC77723-E701-4A7E-BFC1-C975A331CADFQ51743392-86D279F8-DBD2-42CC-9665-21485C94C177Q53211832-D08C89C9-B339-4CB7-B971-9C12457C6787
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antisense strategies.
@ast
Antisense strategies.
@en
type
label
Antisense strategies.
@ast
Antisense strategies.
@en
prefLabel
Antisense strategies.
@ast
Antisense strategies.
@en
P356
P1476
Antisense strategies.
@en
P2093
Stanley T Crooke
P304
P356
10.2174/1566524043360375
P577
2004-08-01T00:00:00Z